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A B S T R A C T
Etiopathogenesis of the laryngopharyngeal reflux has not been sufficiently clarified. It is believed that damage to the
lining of laryngopharynx in laryngopharyngeal disease occurs in the use of acid and pepsin. The diagnosis of reflux
acidic 24-hour Dual probe pH-metry is considered the gold standard. However, since the laryngopharyngeal reflux is of-
ten non-acidic new diagnostic methods are been explored, safe diagnosis of the disease according to symptoms of this un-
characteristic disease. In our study on 45 patients with laryngopharyngeal disease, we have proved that tracking the
value of pepsin in the saliva of a valuable diagnostic indicator of laryngopharyngeal reflux and a valuable indicator of
the success of the treatment.
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Introduction
Pathogenesis and molecular mechanisms of laryngo-
pharyngeal diseases (LPRD) are relatively unknown. It is
believed that in the development of laryngopharyngeal
reflux have a crucial role: the dysfunction of the upper
esophageal sphincter1, prolonged contact with gastric
contents and laryngophyryngeal mucus vagal reflex ac-
tivity in the distal esophagus. According to recent stu-
dies2–5 after exposure of laryngeal mucus of stomach con-
tents containing acid and pepsin, pepsin activity leads to
depletion of the enzyme carbonic anhydrase III (CAIII),
inhibiting the expression of protective protein mucin
2,3,5 A, 5B, Sep70 and Sep53 and E-cadherin who have a
vital role in maintaining cellular integrity of the epithe-
lium3. The most recent research stresses the importance
of the so-called nonacidic or low acidity reflux in the eti-
ology of the LPRD6. It is the cause of this problem in
about 20% of patients with persistent symptoms despite
therapy laryngopharyngeal reflux (LPR) medication to
combat acidity and pepsin. They are held responsible for
the development of mucus injury laryngopharynx. The
former gold standard in diagnosing reflux laryngopha-
ryngeal multichannel 24-hour pH-metry is slightly useful
in non-acidic laryngopharyngeal reflux and it is neces-
sary to combine with multi intraluminal impedance,
which is used in everyday practice and often unavailable
and very invasive for patients. Several recent studies
have investigated the potential use of pepsin as a diag-
nostic marker LPR2,6–9. The aim of this study show that
the values of pepsin in saliva combined with clinical
symptoms (»reflux symptom index« – the Belafsky RSI)
and clinical findings videolaryngoscopy (»reflux finding
score« – the RFS by Belafsky) are significant diagnostic
indicator of disease.
Patients and Methods
In a prospective clinical study included 45 patients
with clinical symptoms and signs LPR, and treated at the
Department for Otorhinolaryngology and Head and
Neck Surgery in the period from September 2010 until
May 2011, and 30 subjects in the control group without
clinical symptoms and signs laryngopharyngeal reflux.
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All subjects on the basis of clinical symptoms of disease
specified »reflux symptom index« – RSI by Belafsky for
suspicion of laryngopharyngeal disease had to be greater
than the seven. All respondents were based on clinical
findings identified videolaryngoscopy »reflux finding
score« – RFS by Belafsky for suspicion of laryngopharyn-
geal disease had to be greater than 10. All subjects un-
derwent esophagogastroduodensocopy (Olympus). Dur-
ing the performance of esophagogastroduodensocopy there
were taken two biopsies from the antrum and two biop-
sies from the corpus of the stomach. Biopsies from the
antrum and corpus of the stomach were fixed in formalin
for histopathologic analysis. Also, all respondents were
sampled saliva for analysis of the value of pepsin in saliva
at baseline and eight weeks after treatment with proton
pump inhibitors. Proton pump inhibitors have ordained
the first four weeks at a dose of 2x40 mg, and then at a
dose of 2x20 mg next four weeks. Eight weeks after ther-
apy, we again found the RSI and RFS by Belafsky. Sam-
ples of saliva were centrifuged for 15 minutes at 1000
rpm and then frozen and stored at –70 °C until analysis.
After we collected all saliva samples, the samples were
dissolved at room temperature. ELISA (USCN Life Sci-
ence Inc. Wuhan, China) according to manufacturer’s in-
structions, we determined the value of pepsin in saliva
samples. From the studies excluded patients who did not
regularly take treatment, which had previously been tak-
ing proton pump inhibitors, patients who had previously
performed radiation of head and neck and patients with
previously demonstrated salivary gland diseases. In sup-
port of data processing applications used the Microsoft
Excel 2003 and SPSS statistical package (SPSS Statistics
17.0, SPSS Inc.) And Statistica (Statistica 8.0, StatSoft,
Inc.). The study considered significant differences con-
firmed the significance level p<0.05.
During the research, ethical principles are respected.
Subjects were given oral and written all information re-
garding participation in the proposed study and gave vol-
untary consent to participate in the study. Confirmation
of the Ethics Commission – an explanation that the re-
search in accordance with ethical principles – issued by
the Ethics Committee of the Clinical Hospital Osijek, in
which research is conducted. Also, the Ethics Committee
for Medical Research, University of Josip Juraj Stross-
mayer gave the opinion and consent of the multidisci-
plinary research ethically acceptable.
Results
In a prospective clinical study included 45 patients
with clinical symptoms and signs LPR (28 women 62.22%
37.78% 17 men) average age of 51.69 years. The control
group consisted of 30 patients without clinical symptoms
and signs laryngopharyngeal reflux (19 women and 11
63.33% 36.67% men) with an average age of 38.87 years.
The average value of pepsin in patients before treatment
was 91.97 ng / ml, while the average value of pepsin after
treatment was 34.96 ng / ml. Table 1. Test results show
that it can accept the hypothesis of the existence of sta-
tistically significant differences in the levels of pepsin be-
fore and after therapy (Z=–5842, p=0.0000). Comparing
the values of pepsin before and after treatment with the
finding of gastroscopy showed a statistically significant
difference in the amount of pepsin in patients with
chronic gastritis (Z=–4703, p=0.000), and that there is a
significant difference in subjects in which the diagnosed
with chronic gastritis and other gastric diseases (Hiatus
hernia, GERD) (Z=–3 517, p=0.000). Based on the re-
sults obtained by the average value of pepsin in the saliva
of subjects in the control group 10.76 ng / ml, with a stan-
dard deviation of 10.16 ng / ml. Based on the median, the
levels of pepsin in the saliva of half of the respondents
was 6.65 ng / ml or less. Comparing the level of pepsin be-
fore therapy in patients with suspected reflux laryngo-
pharyngeal and pepsin in the saliva of the control group
confirmed a statistically significant difference in the
amount of pepsin before therapy and pepsin in the saliva
of the control group (Table 2). Average value of pepsin af-
ter treatment determined by the respondents was for a
24.2 ng / ml higher than the levels of pepsin in the saliva
of the control group, but these values were not statisti-
cally significant (Table 3). The average value of the RFS
(Reflux Finding Score) before therapy was 11.96 average
value of the RFS after therapy was 5.78. The average
value of RSI (Reflux Symptom Index) before treatment
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TABLE 1
DESCRIPTIVE STATISTICAL INDICATOR OF PEPSIN LEVELS





before therapy after therapy
Number of date 45 45
Arithmetic mean 91.97 34.96
Median 17.90 6.40
Minimal value 3.20 1.60
Maximum value 345.10 280.10
Bottom quartile 10.60 3.00
Upper quartile 200.50 23.50
Range of variation 341.90 278.50
Interquartile 189.90 20.50
Standard deviation 110.42 63.85




MEAN RANGE, THE SUM OF RANKS AND MANN-WHITNEY








PATIENTS 45.71 2057.00 Z=–3.753
CONTROL 26.43 793.00 p=0.000
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was 18:02, while the average value of RSI after treat-
ment was 6.78. Based on Spearman rank correlation co-
efficient, we can conclude that the RFS and the RSI be-
fore therapy there is a positive relationship that was
statistically significant (p=0397, p=0.007). Comparing
the RFS and the RSI values with pepsin prior to therapy
there is no statistically significant association (p=0056,
p=0.714), and after treatment (p=0105, p=0.49).
Discussion
LPR is a disease that occurs in nearly 10% of patients
visiting the ENT and about 50% of the hoarseness is
caused by them. Since laryngopharyngeal nonspecific
symptoms of reflux disease and a number of diagnostic
dilemmas certain diagnosis of laryngopharyngeal reflux
is not easy to set up. So far, multi-channel 24-hour
pH-Geometry was considered the gold standard, a meth-
od which is invasive, expensive and limited in application
only with acidic reflux. Since LPR disease often non-acidi
it is necessary to set a new gold standard for diagnosis of
this common ease. As a diagnostic method, a proton
pump inhibitor therapy is indicated, except for good and
adverse effects such as diarrhea, atrophic gastritis, chan-
ges in the absorption of iron and vitamin B12, possible
liver damage. Therefore, if possible, long-term use and
over-prescribing of these drugs is certainly desirable to
avoid11. So far, several studies have shown that pepsin
plays an important role in the development of mucus
damage of laryngopharynx with interaction of acidic and
non-acidic reflux3,4,10 In our study we determined the
value of pepsin in the saliva of subjects with symptoms of
LPR. We found that pepsin is present in the saliva of pa-
tients with laryngopharyngeal reflux and that the value
of pepsin in saliva prior to treatment increased and the
difference was statistically significant compared with the
values of pepsin in the saliva of subjects in the control
group. In 23 subjects (31%) with clinically clear signs of
LPR, the value of pepsin before therapy was comparable
with the levels of pepsin in the control group which
raises doubts about the reliability of the sample. After
completing therapy, proton pump inhibitors, there is no
statistically significant difference in the values of pepsin
in the saliva of the test group and control subjects, which
indicates the contribution to the success of a proton
pump inhibitor therapy. In 5 patients (11%) levels of pep-
sin in saliva after completion of therapy still showed a
significantly increased value of 100.3–280.1 ng / ml, sug-
gesting that in these patients must continue therapy
with inhibitors of the IPP instructions of the American
Academy of Otolaryngology and head and neck surgery.
According to the findings esophagogastroduodensocopy
all respondents had pathological changes in the gastric
mucus, but the value of pepsin did not show a statisti-
cally significant difference with the type of clinical find-
ings in the gastric mucus, we confirmed that LPR and
gastroesophageal reflux are two different diseases. Aver-
age values of RFS and RSI by Belafsky before and after
therapy showed a statistically significant difference.
Conclusion
In this study we have shown that the amount of pep-
sin in the saliva of patients with reflux laringofaringeal-
nim significantly higher than the value of pepsin in the
saliva of subjects in the control group. We have also
shown that the subjects were diagnosed as gastroesopha-
geal reflux disease have significantly higher levels of pep-
sin in saliva in relation to the subjects were diagnosed as
chronic gastritis, suggesting that gastroesophageal re-
flux and laryngopharyngeal reflux two the etiopatho-
genesis of various diseases. We expect that in the near fu-
ture in everyday practice as a diagnostic method LPR
will be introduced in a simple, reliable, sensitive and in-
expensive analysis of pepsin in saliva ELISA test.
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TABLE 3
MEAN RANGE, THE SUM OF RANKS AND MANN-WHITNEY








PATIENTS 38.04 1712.00 Z=–0.022
CONTROL 37.93 1138.00 p=0.983
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ZNA^ENJE PEPSINA IZ SLINE U DIJAGNOSTICI I LIJE^ENJU LARINGOFARINGEALNE
REFLUKSNE BOLESTI
S A @ E T A K
Etiopatogeneza laringofaringealnoga refluksa do danas nije dovoljno razja{njena. Smatra se da o{te}enje sluznice
laringofarinksa u laringofaringealnoj bolesti nastaje djelovanjem kiseline i pepsina. U dijagnostici aciditetnog refluksa
24-satna pH-metrija smatra se zlatnim standardom. Me|utim, budu}i je laringofaringealni refluks ~esto neaciditetan
istra`uju se nove dijagnosti~ke metode sigurnog postavljanja dijagnoze ove po simptomima nekarakteristi~ne bolesti. U
na{em istra`ivanju na 45 ispitanika s laringofaringealnom bole{}u dokazali smo da je pra}enje vrijednosti pepsina u
slini vrijedan dijagnosti~ki pokazatelj laringofaringealnoga refluksa i vrijedan pokazatelj uspje{nosti primijenjene tera-
pije.
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